More recently, a pilot trial was performed at the MD Anderson Cancer Center to evaluate a short course of oral talazoparib (TALA) 1 mg once a day (OD) over 2 months, before starting the standard neoadjuvant chemotherapy in gBRCA1/2m patients with HER2-negative early BC. The gene discussed is ERBB2; the disease is breast cancer.